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ABSTRACT 
Objectives: To evaluate the effect of early intravenous metoprolol on left ventricular (LV) 
strain assessed with feature tracking cardiovascular magnetic resonance (CMR). 
Background: Early intravenous metoprolol before primary percutaneous coronary 
intervention (PCI) in ST-segment elevation myocardial infarction (STEMI) portends better 
outcomes in the METOCARD-CNIC trial.  
Methods: A total of 197 patients with acute anterior STEMI who were enrolled in the 
METOCARD-CNIC trial (100 allocated to intravenous metoprolol before primary PCI and 97 
controls) were evaluated. LV global circumferential strain (GCS) and global longitudinal 
strain (GLS) were measured with feature tracking CMR at 1 week and 6 months after STEMI 
and compared between randomization groups.  
Results: Patients who received early intravenous metoprolol had significantly more 
preserved LV strain compared to the controls at 1 week after STEMI (GCS: -13.9±3.8% 
versus -12.6±3.9%, respectively; P=0.013; GLS: -11.9±2.8% versus -10.9±3.2%, 
respectively; P=0.032). In both groups, LV strain significantly improved during follow-up 
(mean difference between 6-month and 1-week strain for the metoprolol group: GCS: -2.9%, 
95% CI: -3.5% to -2.4; GLS: -2.9%, 95% CI: -3.4 to -2.4; both P<0.001; the control group: 
GCS: -3.4%, 95% CI: -3.9% to -2.8%; GLS: -3.4%, 95% CI: -3.9% to -3.0%; both P<0.001). 
When dividing the overall cohort of patients in quartiles of GCS and GLS, there were 
significantly less patients in the first quartile (i.e. the worst LV systolic function) who received 
early intravenous metoprolol compared to controls at 1 week and 6 months (P<0.05 for GCS 
and GLS at both time points). 
Conclusions: In patients with anterior STEMI, early administration of intravenous metoprolol 
before primary PCI was associated with significantly less patients with severely depressed 
LV GCS and GLS, both at 1 week and 6 months. Feature tracking CMR represents a 
complementary tool to evaluate the benefits of cardioprotective therapies.  
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CONDENSED ABSTRACT 
Feature tracking CMR allows myocardial strain assessment from standard CMR cine 
images. In 197 patients with acute anterior STEMI (100 randomized to intravenous 
metoprolol before primary PCI and 97 controls) GCS and GLS were evaluated with feature 
tracking CMR at 1 week and 6 months after STEMI. Overall, GCS and GLS improved from 1 
week to 6 months after STEMI. Early intravenous metoprolol before primary PCI was 
associated with significantly less patients with severely depressed LV GCS and GLS at both 
time points, supporting its use in clinically stable STEMI population. Feature tracking CMR 
represents a complementary tool to evaluate the benefits of cardioprotective therapies. 
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ABBREVIATIONS LIST 
CI – confidence interval  
CMR – cardiovascular magnetic resonance 
GCS – global circumferential strain 
GLS – global longitudinal strain 
LGE – late gadolinium enhancement 
LV – left ventricle/left ventricular 
LVEF – left ventricular ejection fraction 
PCI – percutaneous coronary intervention 
STEMI – ST-segment elevation myocardial infarction  
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INTRODUCTION  
The long-term treatment with beta-blockers after ST-segment elevation myocardial infarction 
(STEMI) is well established and the benefit appears to be greatest for patients with 
myocardial infarction complicated by heart failure, left ventricular (LV) systolic dysfunction, or 
ventricular arrhythmias (1,2). Current European and American guidelines recommend 
initiating oral beta-blockers in the first 24 hours after STEMI (1,2). The role of routine early, 
intravenous beta-blockers administration prior to primary percutaneous coronary intervention 
(PCI) is less firmly established. In the context of reduced oxygen supply during myocardial 
infarction, beta-blockers have the potential to reduce ischemic injury when administered prior 
to PCI, through their effect on slowing of heart rate, decreasing myocardial contractility, and 
lowering systemic blood pressure. In addition, some beta-blockers have shown to be able to 
reduce reperfusion-injury by inhibiting neutrophils function (3). The Effect of Metoprolol in 
Cardioprotection During an Acute Myocardial Infarction (METOCARD-CNIC) trial showed 
that early administration of intravenous metoprolol before primary PCI significantly reduced 
infarct size 1 week post-STEMI as evaluated by cardiovascular magnetic resonance (CMR) 
imaging (4). In addition, early metoprolol administration was associated with improved long-
term LV ejection fraction (LVEF), fewer indications for cardioverter-defibrillator implantation, 
and fewer heart failure readmissions (5). Accordingly, current European guidelines indicate 
that intravenous beta-blockers should be considered at the time of presentation in STEMI 
patients undergoing primary PCI provided that there are no contraindications, no signs of 
acute heart failure, and the systolic blood pressure is >120 mmHg (1).  
The impact of early intravenous metoprolol on LV myocardial strain has not yet been 
evaluated. In contrast to LVEF, LV strain does not rely on geometrical assumptions, shows 
superior intra- and inter-observer reproducibility and can detect subtle systolic dysfunction in 
patients with preserved LVEF (6,7). Recent development of feature tracking CMR allows 
multidirectional myocardial strain assessment from standard cine images without the need 
for specialized pulse sequences or additional scanning time (8). In the METOCARD-CNIC 
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trial population, we evaluated LV global circumferential (GCS) and longitudinal (GLS) strain 
measured with feature tracking CMR both at 1 week and 6 months after primary PCI. 
 
METHODS  
Patient population 
The present study included patients who were enrolled in the METOCARD-CNIC trial and 
completed 1-week and 6-month CMR study. Briefly, the multicenter randomized 
METOCARD-CNIC clinical trial recruited patients with first anterior STEMI undergoing 
primary PCI (9). A total of 270 patients were randomized to receive up to 15 mg intravenous 
metoprolol before reperfusion versus conventional therapy. All patients received oral 
metoprolol, first dose 12-24 hours after STEMI. Exclusion criteria were Killip class III to IV 
acute heart failure, systolic blood pressure persistently <120 mmHg, PR interval >240 
milliseconds (or type II–III atrioventricular block), heart rate persistently <60 beats/min, or 
active treatment with any beta-blocker agent. Of the initial population, 202 patients 
underwent 2 CMR studies, at 1 week (5 to 7 days) and 6 months after STEMI. Conventional 
CMR parameters of LV dimensions, function and myocardial scar and LV GCS and GLS 
measured with feature tracking analysis were evaluated at both time points for the overall 
population as a single group, and for each randomization treatment arm individually.  
The study was approved by the ethical committees and institutional review boards at 
each participating center. All eligible patients gave written informed consent. 
 
Cardiovascular magnetic resonance 
The CMR protocol has been described in detail elsewhere (9). Data acquisition was 
performed with 1.5 and 3.0 T CMR scanners. LV 2-, 3- and 4-chamber views and a stack of 
contiguous short-axis slices covering the whole LV were acquired with steady-state free 
precession functional cine imaging. Typical acquisition parameters were: voxel size 1.6×2 
mm, slice thickness 8 mm, gap 0 mm, cardiac phases 25-30, TR 3.5, TE 1.7, flip angle 40, 
SENSE 1.5, averages 1, FOV 360 × 360 mm. Subsequently, segmented inversion recovery 
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gradient echo sequence acquired 10-15 minutes after a cumulative dose of 0.2 mmol/kg 
intravenous gadolinium contrast agent (Magnevist, Schering AG, Berlin, Germany) was 
employed for myocardial necrosis/fibrosis imaging. LV volumes, LV mass, LVEF and late 
gadolinium enhancement (LGE) data were analyzed with dedicated software (QMass MR 
7.5; Medis, Leiden, the Netherlands) as described before (9).  
 
Feature tracking CMR analysis 
Feature tracking CMR analysis was performed on steady-state free precession cine images 
with dedicated software (CVI42 v5.3, Circle Cardiovascular Imaging, Calgary, Canada) 
(Figure 1, Videos 1 and 2 in supplementary material). First, the LV endo- and epicardium 
were delineated at end-diastole in the LV 2-, 3- and 4-chamber views and contiguous short-
axis slices and the LV reference points were defined: the mitral annulus and the LV apex in 
long-axis views and the anterior right ventricular insertion point in the short-axis slices. The 
most basal short-axis slices, in which the image plane showed LV myocardium only at end-
diastole but not at end-systole were excluded. The outlined myocardium borders were 
automatically tracked throughout the cardiac cycle with fully automated feature tracking 
analysis. The quality of the myocardium tracking was visually evaluated. Global time-strain 
curves were obtained and peak LV GCS and GLS values were recorded.  
A single observer (TP) performed feature tracking analysis of CMR data. The same 
observer repeated the analysis of 20 randomly selected CMR scans after 4 weeks to assess 
the intra-observer variability. A second observer (JMMC), blinded to the results of the first 
observer, re-measured a different subset of 20 randomly selected CMR scans for the 
assessment of inter-observer variability.  
 
Statistical analysis 
Continuous variables are presented as mean ± standard deviation and categorical variables 
as frequencies (percentages). Patients were divided into 2 groups according to the treatment 
received. Comparisons between the early metoprolol group and the control group were 
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performed using independent samples t-test for continuous variables and Pearson’s Chi 
square test or Fischer’s exact test for categorical variables. Fischer’s exact test was used 
when the expected value of a categorical variable was <5. Comparisons between 1-week 
and 6-month CMR data were performed using paired samples t-test. In addition, the study 
population was divided in quartiles of LV GCS and GLS. The number of patients within the 
first quartile of LV GCS and GLS (worst LV systolic function) at each randomization 
treatment arm (early intravenous metoprolol vs controls) was compared with Pearson’s Chi 
square test at 1 week and 6 months of follow-up. In addition, logistic regression analysis was 
performed to assess the value of LV GCS and GLS 1 week after STEMI to predict LVEF 
normalization (≥50%) at 6 months. Odds ratios and 95% confidence intervals (CI)  were 
calculated and adjusted for infarct size (LGE extent) at 1-week CMR, demographic and 
clinical variables (age, sex, body mass index, presence of hypertension, diabetes, 
dyslipidemia, smoking status) and treatment randomization arm (early intravenous 
metoprolol vs. controls). 
The intra- and inter-observer agreement for GCS and GLS measurements were 
assessed with intraclass correlation coefficients. A two-sided P-value of <0.05 was 
statistically significant and excellent agreement was defined as an intraclass correlation 
coefficient >0.9. All statistical analyses were performed using IBM SPSS Statistics 23 (IBM, 
Armonk, New York). 
 
RESULTS 
Of the initial 202 patients who underwent 2 CMR studies, feature tracking CMR analysis was 
feasible in 197 patients (early metoprolol group: N=100; control group: N=97) and they 
formed the population of the present analysis. LV GLS analysis at 6 months was feasible in 
195 patients (early metoprolol group: N=99; control group: N=96). 
Patients demographics, cardiovascular risk factors, clinical characteristics at 
recruitment and procedural characteristics of the overall population (mean age 58.1 years, 
88% male) and the patients divided according to received randomization treatment 
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(metoprolol vs control) are presented in Table 1. There were no statistically significant 
differences between both groups. Conventional and feature tracking CMR parameters of LV 
structure and function, evaluated at 1 week and 6 months after STEMI for the overall 
population and for each randomization treatment arm individually, are presented in Table 2.  
 
LV conventional and feature tracking CMR parameters 1 week after STEMI 
One week after intervention (metoprolol or control), patients who received early intravenous 
metoprolol showed significantly smaller LV end-systolic volumes, higher LVEF and smaller 
infarct sizes assessed by LGE (Table 2, Figure 2). In addition, patients who received early 
intravenous metoprolol had more preserved LV GCS and GLS than patients in the control 
group (GCS: -13.9±3.8% versus -12.6±3.9%, respectively; P=0.013; GLS: -11.9±2.8% 
versus -10.9±3.2%, respectively; P=0.032).  
 
Changes in LV conventional and feature tracking CMR parameters between 1-week 
and 6-month follow-up after STEMI 
There were significant changes in conventional CMR parameters and LV strain between 1-
week and 6-month follow-up in the overall population and in both study treatment arms 
(Table 3, Figure 2 and 3). LV end-diastolic and end-systolic volumes significantly increased 
over time. However, LV dilation was more pronounced for LV end-diastolic volumes than for 
LV end-systolic volumes, partly explaining the significant improvement of LVEF over time. 
The percentage of LV myocardium with LGE significantly decreased over the 6 months of 
follow-up. In addition, LV GCS and GLS significantly improved over the 6-month follow-up 
(mean difference between 6-month and 1-week strain for the metoprolol group: GCS: -2.9%, 
95% CI: -3.5% to -2.4; GLS: -2.9%, 95% CI: -3.4 to -2.4; both P<0.001; the control group: 
GCS: -3.4%, 95% CI: -3.9% to -2.8%; GLS: -3.4%, 95% CI: -3.9% to -3.0%; both P<0.001). 
 LV GCS and GLS at 1 week after STEMI were significant predictors of LVEF 
normalization (LVEF ≥50%) at 6-month follow-up (Supplementary Table 1). Each 1 percent 
increase in LV GCS was associated with 40.8% higher likelihood of LVEF normalization 
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(P<0.001) and each 1% of increase in LV GLS was associated with 40.9% higher likelihood 
of LVEF normalization at 6 months after STEMI (P<0.001). Both, LV GCS and GLS, 
remained significant predictors of LVEF normalization after adjusting for the extent of LGE 
on 1-week CMR, demographic and clinical variables and treatment randomization arm 
(P<0.001 for both).   
 
LV conventional and feature tracking CMR parameters 6 months after STEMI 
The improvements in LV conventional and feature tracking CMR parameters resulted in non-
significant differences in LV end-diastolic volumes, LV mass and LGE between both 
treatment arms at 6 months (Table 2, Figure 2). However, patients who received early 
intravenous metoprolol still had significantly smaller LV end-systolic volumes and higher 
LVEF. In addition, patients who received early intravenous metoprolol showed a non-
significant trend for more preserved LV strain compared to patients in the control group 
(GCS: -16.9±4.0% versus -15.9±4.4%, respectively; P=0.122; GLS: -14.8±2.9% versus -
14.4±3.0%, respectively; P=0.379).  
 
The effect of early metoprolol on severe LV systolic dysfunction  
When dividing the overall cohort of patients in quartiles of GCS and GLS, there were 
significantly less number of patients receiving early intravenous metoprolol in the first GCS 
and GLS quartile (i.e. the worst LV systolic function), both at 1 week and at 6 months (Table 
4, Figure 4). At 1 week after STEMI, there were 18 patients who received early intravenous 
metoprolol versus 31 patients with the conventional treatment in the first GCS quartile group 
(≥-10.0%) (P=0.023) and 13 patients who received early metoprolol versus 36 controls in the 
first GLS quartile group (≥-9.3%) (P<0.001). At 6 months after STEMI, there were 17 
patients who received early intravenous metoprolol versus 32 patients with the conventional 
treatment in the first GCS quartile group (≥-13.1%) (P=0.009) and 18 patients who received 
early metoprolol versus 31 controls in the first GLS quartile group (≥-12.8%) (P=0.023). 
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Reproducibility of global left ventricular strain measurements 
Excellent intra- and inter-observer variabilities for the feature tracking CMR analysis of GCS 
and GLS were obtained. The intra-observer intraclass correlation coefficients (95% CI) for 
the measurement of LV GCS and GLS were 0.990 (0.975-0.996) and 0.982 (0.955-0.993), 
respectively. Furthermore, the inter-observer intraclass correlation coefficients (95% CI) for 
the measurement of LV GCS and GLS were 0.995 (0.987-0.998) and 0.990 (0.976-0.996), 
respectively.  
 
DISCUSSION 
The present study demonstrates that in patients with anterior STEMI treated with primary 
PCI, early administration of intravenous metoprolol was associated with more preserved LV 
GCS and GLS at 1 week after myocardial infarction as compared to controls. In addition, 
early administration of intravenous metoprolol before primary PCI was associated with 
significantly less patients with severely depressed GCS and GLS both at 1 week and 6 
months. Altogether, these data indicate that early intravenous metoprolol before reperfusion 
improves short and long-term LV systolic dysfunction as evaluated with feature tracking 
CMR. 
 
LV conventional and feature tracking CMR parameters 1 week after STEMI 
Acute myocardial infarction results in myocardial cell necrosis and changes in extracellular 
collagen matrix that portend adverse consequences on LV structure and function (10). While 
early intravenous beta-blocker administration offers physiological rationale for lowering the 
myocardial infarction burden, their routine use has been disputed over the last decades due 
to the conflicting data on patients outcome (11) The METOCARD-CNIC trial was the first 
randomized control trial in the modern era of primary PCI in STEMI patients, showing that 
early administration of intravenous metoprolol resulted in significant reduction of LV end-
systolic volumes, increase in LVEF and smaller LGE-assessed infarct size 1 week after 
anterior STEMI, as evaluated by CMR imaging (4). The present study provides additional 
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information on the effect of early intravenous metoprolol on LV systolic function by means of 
circumferential and longitudinal shortening, assessed with novel feature tracking CMR 
algorithm. This is important since LV strain with speckle tracking echocardiography has been 
shown to be a more sensitive marker of LV dysfunction (7) and to provide incremental 
prognostic information over LVEF in the STEMI population (12). Recently, clinical 
implications of feature tracking CMR in STEMI have been demonstrated (13,14). Our results 
show that GCS and GLS were more preserved in patients who received early intravenous 
metoprolol, supporting the rationale to use beta-blocker intravenously in clinically stable 
STEMI patients before primary PCI (1). 
 
Time course of LV structural and functional changes after STEMI 
In the healing process of acute myocardial infarction important structural and functional 
changes take place in both the infarct area and the remote zone (10). Several studies have 
focused on LV remodeling after acute myocardial infarction (15-17). In a large prospective 
STEMI registry including 507 patients treated with primary PCI and imaged with CMR at 1 
week and 6 months, LV end-diastolic volume increased (from 79±21 mL/m2 to 81±23 mL/m2; 
P=0.06) and LV end-systolic volume decreased (from 41±19 mL/m2 to 39±21 mL/m2; 
P=0.02) over time (16). This resulted in a significant increase in LVEF (from 50±12% to 
54±13%, respectively; P<0.001). In the present study including a homogenous population 
with anterior STEMI patients treated with primary PCI, LV end-diastolic and LV end-systolic 
volumes both increased significantly over time in patients receiving early intravenous 
metoprolol as well as in controls (Table 3, Figure 2 and 3). However, the increase was 
proportionally larger for LV end-diastolic volume than for LV end-systolic volume, resulting in 
an increase in LVEF. Furthermore, several authors have reported a reduction in infarct size, 
assessed with LGE CMR in STEMI patients treated with primary PCI (16,18). Engblom et al. 
(18) showed a progressive decrease of LGE, expressed as the percentage of total LV mass, 
from days 1, 7, 42 to 182; however, there was no significant additional reduction of 
hyperenhanced myocardium at 1 year. The LGE reduction occurred predominantly during 
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the first week after infarction (63% of the total 1-year reduction). In addition, Bodi et al. (16) 
reported significant reduction of LGE from 1 week to 6 months after STEMI (21±14% and 
17±12%, respectively; P<0.001). This is in line with the results of the present study, which 
also demonstrated a decrease in LV hyperenhancement from 1 week to 6 months post-
infarction.  
In addition, the present study evaluated LV strain with feature tracking CMR. LV 
strain has been extensively studied with speckle tracking echocardiography after acute 
myocardial infarction (19). On the other hand, global LV strain with CMR after myocardial 
infarction has been less extensively evaluated, but a few studies investigated the time 
changes of regional LV strain, using different myocardial tagging techniques (20,21). 
Kidambi et al. (20) showed an improvement of infarct zone peak systolic circumferential 
strain from day 2 to day 90 in 39 patients after STEMI treated with primary PCI, using 
complementary spatial modulation of magnetization myocardial tagging technique. Neizel et 
al. (21) demonstrated an improvement in peak systolic circumferential strain in the 
myocardial segments with >50% transmural LGE (P<0.05) with strain-encoded imaging. The 
present study is, however, the first to assess the time course of GCS and GLS in a large 
anterior STEMI population with feature tracking CMR. We demonstrated an overall 
improvement of 3.2% of GCS and GLS between 1-week and 6-month follow-up (P<0.001 for 
both).  
 
The effect of metoprolol on long-term results  
The results of the METOCARD-CNIC trial have shown long-term benefit of early intravenous 
metoprolol after acute anterior STEMI (5). Patients who received early intravenous 
metoprolol had smaller LV end-systolic volumes and more preserved LVEF at 6 months after 
STEMI, however there were no statistically significant differences in LGE-assessed infarct 
size between both treatment arms. In the present analysis, GCS and GLS showed a 
tendency towards more preserved values in the metoprolol group, but the differences did not 
reach the level of statistical significance. These results suggest that GCS and GLS are more 
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closely related to myocardial infarct size, assessed with LGE CMR, than to changes in LV 
volumes, described by LVEF. This is in line with the literature, showing that GLS with 
echocardiography is a better predictor of LGE-assessed infarct size compared to LVEF, 
whether measured in the acute phase after revascularization or at follow-up (22,23). 
The different effects of metoprolol on GCS and GLS between 1-week and 6-month 
follow-up might be explained by the kinetics of the healing process of myocardial infarction. 
Edema is a very dynamic process during the first week after myocardial infarction (24), and 
strain closely associates with its intensity and volume (20). Moreover, cardioprotective 
therapies may affect the extent and intensity of post-myocardial infarction edema (25). We 
may reasonably assume that the differences in LV GCS and GLS between both treatment 
arms were more pronounced in the acute phase because of a blunted edematous reaction in 
metoprolol treated patients as compared to controls and have diluted at 6-month follow-up 
due an overall large resorption of edema and necrotic tissue (26,27).  
Importantly however, when dividing the overall cohort of patients in quartiles of GCS 
and GLS, there were significantly less number of patients receiving early intravenous 
metoprolol in the first GCS and GLS quartile (i.e. the worst LV systolic function), both at 1 
week and at 6 months after STEMI (Figure 4). This shows that early metoprolol 
administration has a long-term beneficial effect on the healing process of STEMI and 
prevents severe LV systolic dysfunction. Our results support the use of early intravenous 
metoprolol in STEMI patients without contraindications to beta-blockers undergoing primary 
PCI. 
 
Study limitations 
Feature tracking is a novel technique to assess LV strain with CMR. Recommendations on 
how to perform feature tracking analysis are lacking, there are no accepted standard 
reference values for LV strain and the agreement between different vendors of feature 
tracking software is largely unknown (28). However, LV strain with feature tracking CMR has 
shown to closely correlate with myocardial tagging and speckle tracking echocardiography 
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and demonstrated superior intra- and inter-observer variability compared to both methods 
(29,30). Furthermore, evaluation of LV strain was not a predefined study endpoint of the 
METOCARD-CNIC trial. Of the initial 202 patients who underwent 2 CMR studies in the 
METOCARD-CNIC trial, 5 patients were excluded from the LV strain analysis (7 patients 
from the analysis of GLS at 6 months) due to poor CMR cine image quality, which may have 
influenced our results. However, 98% (97%) feasibility of strain assessment with feature 
tracking CMR is similar to what has been described before (29,30).  
 
CONCLUSION 
Early intravenous metoprolol is associated with improved LV strain at 1 week after the acute 
anterior STEMI. Furthermore, early intravenous metoprolol is associated with less patients 
having worst LV systolic function at 1-week and at 6-month follow-up, compared to controls. 
In conclusion, early metoprolol administration before primary PCI reduces the incidence of 
severe LV systolic dysfunction, both at short- and long-term follow-up as evaluated by 
feature tracking CMR. 
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PERSPECTIVES 
Competency in medical knowledge  
Recent development of feature tracking CMR allows multidirectional myocardial strain 
assessment from standard CMR cine images without the need for specialized pulse 
sequences or additional scanning time. Early intravenous metoprolol in acute anterior STEMI 
before primary PCI was associated with significantly less patients with severely depressed 
LV strain at follow-up. Feature tracking CMR provides a powerful complementary tool to 
evaluate the benefits of cardioprotective therapies. 
 
Translational outlook 
Further studies are required to elucidate whether LV strain assessment with feature tracking 
CMR provides incremental prognostic information on LV remodeling and patients outcome 
after STEMI. 
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Figure 1: Feature tracking cardiovascular magnetic resonance. A: Left ventricular (LV) 
mid-cavity short-axis and 4-chamber long-axis end-diastolic steady-state free precession 
images. LV endo- and epicardium (red and green lines) were delineated and LV reference 
points were defined: the anterior right ventricular insertion point in the short-axis view and 
the mitral annulus and LV apex in the 4-chamber view. The same method was repeated in 
the remaining long- and short-axis slices. B and C: Visual evaluation of myocardium tracking 
(Video 1 and 2 in supplementary material). The interventricular septum and LV anterior wall 
in the short-axis view and the mid-to-apical septum and apex in 4-chamber view (infarcted 
area) show impaired deformation compared to the other myocardial segments (B = end-
diastole, C = end-systole). D: Global time-strain curves were obtained and peak global 
circumferential strain (-11.9%, top image) and peak global longitudinal strain (-10.2%, 
bottom image) values were recorded. 
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Figure 2: Time course and effect of treatment randomization on conventional and 
feature tracking cardiovascular magnetic resonance parameters after ST-segment 
elevation myocardial infarction. Left ventricular end-diastolic volume (LVEDV) (A), left 
ventricular end-systolic volume (LVESV) (B), left ventricular ejection fraction (LVEF) (C), late 
gadolinium enhancement (LGE) (D), peak global circumferential strain (GCS) (E) and peak 
global longitudinal strain (GLS) (F) in the early intravenous metoprolol and the control group, 
at 1 week and at 6 months after the acute event. The asterisks represent the mean values 
and the error bars represent the standard errors of the mean. P-values describe the 
statistical significance between both treatment arms at each time point. 
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Figure 3: Time course of conventional and feature tracking cardiovascular magnetic 
resonance parameters after ST-segment elevation myocardial infarction in the overall 
population. Left ventricular end-diastolic volume (LVEDV) (A), left ventricular end-systolic 
volume (LVESV) (B), left ventricular ejection fraction (LVEF) (C), late gadolinium 
enhancement (LGE) (D), peak global circumferential strain (GCS) (E) and peak global 
longitudinal strain (GLS) (F) in the overall population at 1 week and at 6 months after the 
acute event. Dots are individual patient data. Blue lines represent the mean ± standard error 
of the mean. P-values describe the statistical significance between the two time points.  
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Figure 4: Number of patients within the first quartile of LV GCS and GLS (worst LV 
systolic function) in the early metoprolol group versus controls at 1-week and 6-
month follow-up. Patients in the first global circumferential strain (GCS) and global 
longitudinal strain (GLS) quartile (worst LV systolic function) were compared according to the 
treatment received (early intravenous metoprolol vs conventional therapy) at 1 week and at 6 
months after acute ST-segment elevation myocardial infarction.  
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Table 1: Patients demographics, cardiovascular risk factors, procedural 
characteristics and discharge medication 
 Total 
(N=197) 
Metoprolol 
(N=100) 
Control 
(N=97) 
p-value 
Demographics 
Age (years) 58.1±11.3 57.8±12.3 58.4±10.1 0.698 
Sex (male) 173 (88) 87 (87) 86 (89) 0.865 
BMI (kg/m2) 27.6±3.5 27.6±3.5 27.6±3.5 0.900 
Cardiovascular risk factors 
Hypertension 74 (38) 37 (37) 37 (38) 0.955 
Diabetes mellitus 39 (20) 21 (21) 18 (19) 0.616 
Dyslipidemia 85 (43) 43 (43) 42 (43) 0.935 
Smoking* 126 (64) 64 (64) 62 (64) 0.839 
Clinical status at recruitment 
Killip class II† 19 (10) 8 (8) 11 (11) 0.441 
Systolic BP (mmHg) 142±19 142±18 142±19 0.949 
Diastolic BP (mmHg) 88±16 89±16 87±15 0.266 
Heart rate (bpm) 82±13 82±14 81±13 0.539 
Procedural characteristics 
Ischemia duration (min) 194±65 197±62 191±68 0.488 
TIMI grade 0-1 flow 
before primary PCI 
163 (83) 80 (80) 83 (86) 0.373 
Successful PCI (TIMI 
grade 2-3 flow) 
194 (99) 100 (100) 94 (97) 0.117 
BMI = body mass index; PCI = percutaneous coronary intervention; TIMI = Thrombolysis in 
Myocardial Infarction. 
*smoking was defined as current or quitted <10 years ago 
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†all other patients were Killip class I (Killip class III to IV were study’s exclusion criteria)  
30 
 
Table 2: Effect of treatment randomization on conventional and feature tracking CMR parameters 
 
1 week 6 months 
Overall 
(N=197) 
Metoprolol 
(N=100) 
Control 
(N=97) 
Mean difference 
[95% CI] 
p-value 
Overall 
(N=197) 
Metoprolol 
(N=100) 
Control 
(N=97) 
Mean difference 
[95% CI] 
p-value 
LVEDV (mL) 172.6±36.2 169.8±33.4 175.5±38.8 -5.6 [-15.8 to 4.5] 0.276 191.6±42.6 187.0±38.8 196.5±45.9 -9.5 [-21.5 to 2.5] 0.119 
LVESV (mL) 97.8±31.3 92.9±26.6 102.8±34.9 -9.8 [-18.6 to -1.1] 0.028 104.4±40.8 98.2±36.1 110.8±44.5 -12.6 [-24.1 to -1.2] 0.031 
LVEF (%) 44.2±9.4 45.8±9.1 42.6±9.6 3.2 [0.6 to 5.8] 0.017 47.0±10.8 48.7±10.0 45.3±11.4 3.4 [0.4 to 6.4] 0.028 
LV mass (g) 111.5±25.4 109.1±25.2 113.9±25.5 -4.7 [-11.9 to 2.4] 0.192 85.7±17.6 84.6±17.4 86.8±17.7 -2.3 [-7.2 to 2.7] 0.371 
LGE (%) 22.7±12.8 20.9±11.6 24.7±13.8 -3.8 [-7.4 to -0.2] 0.039 16.9±9.7 15.7±9.5 18.0±9.7 -2.3 [-5.1 to 0.5] 0.104 
LV GCS (%) -13.3±3.9 -13.9±3.8 -12.6±3.9 -1.4 [-2.4 to -0.3] 0.013 -16.4±4.2 -16.9±4.0 -15.9±4.4 -0.9 [-2.1 to 0.3] 0.122 
LV GLS (%) -11.4±3.0 -11.9±2.8 -10.9±3.2 -0.9 [-1.8 to -0.1] 0.032 -14.6±3.0 -14.8±2.9 -14.4±3.0 -0.4 [-1.2 to 0.5] 0.379 
CI = confidence interval; CMR = cardiovascular magnetic resonance; GCS = global circumferential strain; GLS = global longitudinal strain; LGE 
= late gadolinium enhancement; LV = left ventricular; LVEDV = left ventricular end-diastolic volume; LVEF = left ventricular ejection fraction; 
LVESV = left ventricular end-systolic volume. 
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Table 3: Time course of LV conventional and feature tracking CMR parameters after STEMI  
 
Overall (N=197) Metoprolol (N=100) Control (N=97) 
Mean 
difference 
95% CI p-value 
Mean 
difference 
95% CI p-value 
Mean 
difference 
95% CI p-value 
LVEDV (mL) 18.9 15.3 to 22.5 <0.001 16.4 11.6 to 21.2 <0.001 21.5 16.2 to 26.8 <0.001 
LVESV (mL) 6.7 3.4 to 9.9 <0.001 4.9 0.4 to 9.3 0.032 8.5 3.6 to 13.4 0.001 
LVEF (%) 2.7 1.8 to 3.6 <0.001 2.9 1.5 to 4.2 <0.001 2.6 1.3 to 3.9 <0.001 
LV mass (g) -25.8 -28.5 to -23.2 <0.001 -24.6 -28.3 to -20.9 <0.001 -27.0 -30.9 to -23.1 <0.001 
LGE (%) -5.8 -6.7 to -4.8 <0.001 -5.1 -6.5 to -3.8 <0.001 -6.5 -7.8 to -5.1 <0.001 
LV GCS (%) -3.2 -3.5 to -2.8 <0.001 -2.9 -3.5 to -2.4 <0.001 -3.4 -3.9 to -2.8 <0.001 
LV GLS (%) -3.2 -3.5 to -2.8 <0.001 -2.9 -3.4 to -2.4 <0.001 -3.4 -3.9 to -3.0 <0.001 
CI = confidence interval; CMR = cardiovascular magnetic resonance; GCS = global circumferential strain; GLS = global longitudinal strain; LGE 
= late gadolinium enhancement; LV = left ventricular; LVEDV = left ventricular end-diastolic volume; LVEF = left ventricular ejection fraction; 
LVESV = left ventricular end-systolic volume; STEMI = ST-segment elevation myocardial infarction.  
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Table 4: Number of patients in GCS and GLS quartiles at 1 week and 6 months after 
STEMI 
 LV GCS 1 week 
1st quartile 
(≥-10.0%) 
2nd quartile 
(-10.0% to -13.1%) 
3rd quartile 
(-13.1% to -16.3%) 
4th quartile 
(<-16.3%) 
Metoprolol 18 22 34 26 
Control 31 28 15 23 
 LV GLS 1 week 
1st quartile 
(≥-9.3%) 
2nd quartile 
(-9.3% to -11.3% 
3rd quartile 
(-11.3% to -13.2%) 
4th quartile 
(<-13.2%) 
Metoprolol 13 34 25 28 
Control 36 16 25 20 
 LV GCS 6 months 
1st quartile 
(≥-13.1%) 
2nd quartile 
(-13.1% to -16.4%) 
3rd quartile 
(-16.4% to -19.8%) 
4th quartile 
(<-19.8%) 
Metoprolol 17 30 27 26 
Control 32 20 22 23 
 LV GLS 6 months 
1st quartile 
(≥-12.8%) 
2nd quartile 
(-12.8% to -15.0%) 
3rd quartile 
(-15.0% to -16.8%) 
4th quartile 
(<-16.8%) 
Metoprolol 18 26 29 26 
Control 31 23 20 22 
GCS = global circumferential strain; GLS = global longitudinal strain; STEMI = ST-segment 
elevation myocardial infarction. 
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SUPPLEMENTARY MATERIAL 
 
Table 1: Left ventricular ejection fraction (LVEF), left ventricular global circumferential (GCS) and longitudinal (GLS) strain at 1 week 
after myocardial infarction as predictors of LVEF normalization (LVEF ≥50%) at 6 months after the acute event 
 Univariate analysis Multivariate analysis 1* Multivariate analysis 2** 
Odds ratio 95% CI P-value Odds ratio 95% CI P-value Odds ratio 95% CI P-value 
LVEF (%) 1.289 1.203-1.382 <0.001 1.190 1.100-1.286 <0.001 1.231 1.129-1.342 <0.001 
GCS (%) 0.592 0.513-0.682 <0.001 0.723 0.619-0.843 <0.001 0.715 0.610-0.839 <0.001 
GLS (%) 0.591 0.505-0.692 <0.001 0.718 0.600-0.860 <0.001 0.666 0.542-0.819 <0.001 
CI = confidence interval. 
*adjusted for the extent of late gadolinium enhancement (LGE) on 1-week cardiovascular magnetic resonance (CMR) 
** adjusted for the extent of LGE on 1-week CMR, age, sex, body mass index, presence of hypertension, diabetes, dyslipidemia, smoking 
status and treatment randomization arm (early intravenous metoprolol vs control) 
 
Video 1: Visual evaluation of feature tracking in left ventricular short-axis slices 
Video 2: Visual evaluation of feature tracking in left ventricular long-axis slices 
 
